tiprankstipranks
Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
PremiumThe FlyShuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per share
2M ago
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
Premium
Company Announcements
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
2M ago
Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine
Premium
The Fly
Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine
2M ago
Shuttle Pharmaceuticals expands clinical trial site enrollment for Phase 2 trial
PremiumThe FlyShuttle Pharmaceuticals expands clinical trial site enrollment for Phase 2 trial
3M ago
Shuttle Pharmaceuticals announces issuance of U.S. patent HDAC inhibitors
Premium
The Fly
Shuttle Pharmaceuticals announces issuance of U.S. patent HDAC inhibitors
4M ago
Shuttle Pharmaceuticals gets ODD for IPdR to treat brain tumors
Premium
The Fly
Shuttle Pharmaceuticals gets ODD for IPdR to treat brain tumors
4M ago
Shuttle Pharmaceuticals announces publication of manuscript on SP-1-303
PremiumThe FlyShuttle Pharmaceuticals announces publication of manuscript on SP-1-303
5M ago
Shuttle Pharmaceuticals Welcomes New CFO Timothy Lorber
Premium
Company Announcements
Shuttle Pharmaceuticals Welcomes New CFO Timothy Lorber
6M ago
Shuttle Pharmaceuticals appoints Timothy Lorber as CFO
Premium
The Fly
Shuttle Pharmaceuticals appoints Timothy Lorber as CFO
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100